SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Spyre Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$84.72+4.82 (+6.03%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
96M of 88M shares
Institutional holders
265
91 new, 21 sold out
Net institutional buying
15M
In Q2 2026
Insider trades, 12 months
0 buys · 79 sales
Net sold $436.71M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Tomas Kiselak | 9,667,201 | 9.99% | 13D (active) amendment | Jun 23, 2026 |
| Peter Harwin | 9,016,702 | 9.99% | 13D (active) amendment | Apr 16, 2026 |
| FMR LLC | 7,623,881 | 15.00% | 13G (passive) amendment | Nov 12, 2024 |
| Senai Asefaw, M.D. | 4,457,450 | 5.10% | 13G (passive) | Sep 24, 2026 |
| Joseph Edelman | 4,319,496 | 5.00% | 13G (passive) | Apr 15, 2026 |
| BlackRock, Inc. | 3,962,635 | 6.60% | 13G (passive) amendment | Jun 30, 2025 |
| RTW Investments, LP | 3,621,996 | 6.20% | 13G (passive) amendment | Dec 31, 2024 |
| Peter E. Deutsch | 3,550,276 | 6.99% | 13G (passive) | Oct 14, 2024 |
| Tang Capital Management, LLC | 3,200,000 | 5.30% | 13G (passive) | Apr 24, 2025 |
| Harwin Peter Evan | 10,185,961 | 9.99% | 13D (active) amendment | Oct 7, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SYRE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 13,026,187 | 14.77% | $1.16B | +1,245,163 | 0.05% |
| BlackRock, Inc. | 6,506,605 | 7.38% | $577.66M | +985,384 | 0.01% |
| Perceptive Advisors LLC | 4,319,496 | 4.90% | $383.48M | +536,271 | 5.76% |
| Rtw Investments, LP | 4,251,996 | 4.82% | $377.49M | +80,000 | 3.22% |
| Paradigm Biocapital Advisors LP | 3,840,778 | 4.36% | $340.98M | +1,883,512 | 6.38% |
| Vanguard Capital Management LLC | 3,448,681 | 3.91% | $306.17M | +391,280 | 0.01% |
| State Street Corp | 3,057,416 | 3.47% | $271.44M | +450,385 | 0.01% |
| VR Adviser, LLC | 2,985,448 | 3.39% | $265.05M | −700,000 | 8.04% |
| Price T Rowe Associates Inc /Md/ | 2,960,855 | 3.36% | $262.87K | +1,362,125 | 0.03% |
| Driehaus Capital Management LLC | 2,799,166 | 3.17% | $248.51M | +8,381 | 1.44% |
| Geode Capital Management, LLC | 2,562,265 | 2.91% | $239.26M | +841,353 | 0.01% |
| Vanguard Portfolio Management LLC | 2,330,098 | 2.64% | $206.87M | +1,744,968 | 0.01% |
| Capital World Investors | 2,315,553 | 2.63% | $205.57M | +1,648,989 | 0.02% |
| Jupiter Topco LLC | 2,206,936 | 2.50% | $195.88M | New | 0.08% |
| TCG Crossover Management, LLC | 1,900,582 | 2.16% | $168.73M | – | 4.06% |
| Tang Capital Management LLC | 1,892,200 | 2.15% | $167.99M | – | 7.63% |
| Bank Of America Corp /De/ | 1,777,854 | 2.02% | $157.84M | +549,761 | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 1,722,300 | 1.95% | $152.91M | New | 0.21% |
| Wellington Management Group Llp | 1,581,505 | 1.79% | $140.41M | −243,306 | 0.02% |
| Goldman Sachs Group Inc | 1,478,059 | 1.68% | $131.22M | +1,208,121 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 265 | 96M | 100.0% | 91 / 104 | 56 / 21 | 27M | 12M |
| Q1 2026 | 198 | 83M | 94.0% | 58 / 67 | 49 / 11 | 12M | 7M |
| Q4 2025 | 153 | 81M | 91.8% | 30 / 76 | 27 / 14 | 23M | 6M |
| Q3 2025 | 137 | 65M | 73.2% | 22 / 44 | 43 / 13 | 5M | 4M |
| Q2 2025 | 129 | 64M | 72.2% | 18 / 63 | 26 / 17 | 6M | 4M |
| Q1 2025 | 129 | 62M | 70.4% | 20 / 53 | 34 / 21 | 7M | 5M |
| Q4 2024 | 131 | 60M | 67.9% | 34 / 62 | 21 / 21 | 13M | 5M |
| Q3 2024 | 119 | 51M | 58.3% | 31 / 42 | 24 / 18 | 10M | 7M |
| Q2 2024 | 107 | 51M | 57.8% | 29 / 47 | 17 / 23 | 21M | 2M |
| Q1 2024 | 102 | 32M | 36.0% | 54 / 20 | 15 / 6 | 9M | 5M |
| Q4 2023 | 54 | 28M | 31.8% | 30 / 16 | 4 / 3 | 25M | 0M |
| Q3 2023 | 27 | 3M | 3.7% | 27 / 0 | 0 / 0 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SYRE | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 2,780,536 | 3.15% | $246.86M | 0.26% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,576,969 | 2.92% | $189.41M | 0.19% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,482,298 | 2.82% | $220.38M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,911,678 | 2.17% | $169.72M | 0.20% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,326,035 | 1.50% | $117.73M | 1.10% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 896,559 | 1.02% | $79.60M | 0.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 886,177 | 1.01% | $78.67M | 0.08% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 857,347 | 0.97% | $84.30M | 3.83% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 814,290 | 0.92% | $80.07M | 0.24% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 777,720 | 0.88% | $76.47M | 0.87% | Jul 31, 2026 |
| Select Health Care Portfolio | 760,000 | 0.86% | $55.86M | 0.97% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 749,630 | 0.85% | $55.10M | 0.20% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 711,845 | 0.81% | $63.20M | 0.53% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 687,511 | 0.78% | $61.04M | 0.40% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 673,799 | 0.76% | $59.82M | 0.41% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Cameron Turtle | Chief Executive Officer, Director | 552,940 | 0.63% | Sep 3, 2026 |
| Scott L. Burrows | Chief Financial Officer | 79,762 | 0.09% | Sep 3, 2026 |
| Heidy King-Jones | See Remarks | 3,245 | 0.00% | Sep 3, 2026 |
| Sheldon Sloan | Chief Medical Officer | 8,334 | 0.01% | Jul 2, 2026 |
| Jeffrey W. Albers | Director | 9,360 | 0.01% | Aug 10, 2026 |
| Michael Thomas Henderson | Director | 68,606 | 0.08% | Jun 23, 2026 |
| Healthcare Fund II L.P. Fairmount | Director | 1,190,497 | 1.35% | Jun 23, 2026 |
| Tomas Kiselak | Director | 9,460,540 | 10.73% | Jun 23, 2026 |
| Funds Management LLC Fairmount | Director | 812,076 | 0.92% | Jun 23, 2026 |
| Peter Evan Harwin | Director | 4,830,177 | 5.48% | Jun 23, 2026 |
| Mark C. McKenna | Director | – | – | May 29, 2026 |
| Laurie Stelzer | Director | – | – | May 29, 2026 |
| Sandra Milligan | Director | – | – | May 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Heidy King-Jones See Remarks | Sep 2, 2026 | Option exercise | +400 | $14.50 | $5.80K | 3,245 |
| Heidy King-Jones See Remarks | Sep 2, 2026 | Sale(10b5-1 plan) | −400 | $90.00 | $36.00K | 2,845 |
| Scott L. Burrows Chief Financial Officer | Sep 2, 2026 | Sale(10b5-1 plan) | −18,232 | $89.35 | $1.63M | 79,762 |
| Heidy King-Jones See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −400 | $89.38 | $35.75K | 2,845 |
| Heidy King-Jones See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −6,206 | $88.17 | $547.18K | 3,245 |
| Heidy King-Jones See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −16,548 | $87.20 | $1.44M | 9,451 |
| Heidy King-Jones See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −4,845 | $86.40 | $418.61K | 25,999 |
| Heidy King-Jones See Remarks | Sep 1, 2026 | Option exercise | +27,999 | $14.50 | $405.99K | 30,844 |
| Cameron Turtle Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −3,700 | $88.06 | $325.82K | 552,940 |
| Cameron Turtle Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −400 | $89.07 | $35.63K | 552,540 |
| Cameron Turtle Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −2,500 | $86.36 | $215.90K | 565,040 |
| Cameron Turtle Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −8,400 | $87.15 | $732.06K | 556,640 |
| Scott L. Burrows Chief Financial Officer | Sep 1, 2026 | Option exercise | +7,500 | $14.50 | $108.75K | 105,494 |
| Scott L. Burrows Chief Financial Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −4,384 | $87.11 | $381.89K | 100,210 |
| Scott L. Burrows Chief Financial Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −900 | $86.25 | $77.63K | 104,594 |
| Scott L. Burrows Chief Financial Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −2,016 | $88.03 | $177.47K | 98,194 |
| Scott L. Burrows Chief Financial Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −200 | $89.04 | $17.81K | 97,994 |
| Jeffrey W. Albers Director | Aug 7, 2026 | Sale(10b5-1 plan) | −10,000 | $104.68 | $1.05M | 9,360 |
| Jeffrey W. Albers Director | Aug 7, 2026 | Sale(10b5-1 plan) | −8,000 | $104.38 | $835.04K | 19,360 |
| Jeffrey W. Albers Director | Aug 7, 2026 | Sale(10b5-1 plan) | −5,000 | $104.47 | $522.35K | 0 |
| Jeffrey W. Albers Director | Aug 7, 2026 | Option exercise | +5,000 | $10.39 | $51.95K | 5,000 |
| Cameron Turtle Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −16 | $97.46 | $1.56K | 567,540 |
| Cameron Turtle Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −1,392 | $96.82 | $134.77K | 567,556 |
| Cameron Turtle Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −5,635 | $95.93 | $540.57K | 568,948 |
| Cameron Turtle Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −7,157 | $95.10 | $680.63K | 574,583 |
| Cameron Turtle Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −800 | $93.97 | $75.18K | 581,740 |
| Scott L. Burrows Chief Financial Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −100 | $97.10 | $9.71K | 97,994 |
| Scott L. Burrows Chief Financial Officer | Aug 3, 2026 | Option exercise | +7,500 | $14.50 | $108.75K | 105,494 |
| Scott L. Burrows Chief Financial Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −5,100 | $95.21 | $485.57K | 100,394 |
| Scott L. Burrows Chief Financial Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −2,300 | $96.30 | $221.49K | 98,094 |
| Sheldon Sloan Chief Medical Officer | Jul 1, 2026 | Option exercise | +8,334 | $27.46 | $228.85K | 8,334 |
| Sheldon Sloan Chief Medical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −6,500 | $87.52 | $568.88K | 1,834 |
| Sheldon Sloan Chief Medical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −1,834 | $88.34 | $162.02K | 0 |
| Scott L. Burrows Chief Financial Officer | Jul 1, 2026 | Option exercise | +7,500 | $14.50 | $108.75K | 105,494 |
| Scott L. Burrows Chief Financial Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −1,725 | $88.37 | $152.44K | 97,994 |
| Scott L. Burrows Chief Financial Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −5,775 | $87.55 | $505.60K | 99,719 |
| Cameron Turtle Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −10,176 | $87.44 | $889.79K | 587,364 |
| Cameron Turtle Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −590 | $88.91 | $52.46K | 582,540 |
| Cameron Turtle Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −4,234 | $88.12 | $373.10K | 583,130 |
| Scott L. Burrows Chief Financial Officer | Jun 25, 2026 | Option exercise | +15,000 | $14.50 | $217.50K | 112,994 |
| Scott L. Burrows Chief Financial Officer | Jun 25, 2026 | Sale | −10,000 | $87.14 | $871.40K | 97,994 |
| Scott L. Burrows Chief Financial Officer | Jun 25, 2026 | Sale | −5,000 | $87.12 | $435.60K | 107,994 |
| Funds Management LLC Fairmount Director | Jun 23, 2026 | Sale | −4,684,781 | $85.31 | $399.66M | 0 |
| Funds Management LLC Fairmount Director | Jun 23, 2026 | Conversion | +666,680 | – | – | 4,684,781 |
| Michael Thomas Henderson Director | Jun 22, 2026 | Sale(10b5-1 plan) | −20,000 | $100.00 | $2.00M | 68,606 |
| Sheldon Sloan Chief Medical Officer | Jun 3, 2026 | Sale(10b5-1 plan) | −8,333 | $75.00 | $624.98K | 0 |
| Sheldon Sloan Chief Medical Officer | Jun 3, 2026 | Option exercise | +8,333 | $27.46 | $228.82K | 8,333 |
| Scott L. Burrows Chief Financial Officer | Jun 1, 2026 | Option exercise | +7,500 | $14.50 | $108.75K | 105,494 |
| Scott L. Burrows Chief Financial Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −1,801 | $69.75 | $125.62K | 103,693 |
| Scott L. Burrows Chief Financial Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −2,599 | $70.77 | $183.93K | 101,094 |
| Scott L. Burrows Chief Financial Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −3,100 | $72.06 | $223.39K | 97,994 |
| Cameron Turtle Chief Executive Officer, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −3,557 | $69.40 | $246.86K | 608,983 |
| Cameron Turtle Chief Executive Officer, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −8,149 | $70.50 | $574.50K | 600,834 |
| Cameron Turtle Chief Executive Officer, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −3,294 | $71.38 | $235.13K | 597,540 |
| Michael Thomas Henderson Director | May 8, 2026 | Sale(10b5-1 plan) | −33,513 | $73.72 | $2.47M | 132,689 |
| Michael Thomas Henderson Director | May 8, 2026 | Sale(10b5-1 plan) | −19,269 | $75.35 | $1.45M | 88,606 |
| Michael Thomas Henderson Director | May 8, 2026 | Sale(10b5-1 plan) | −24,814 | $74.76 | $1.86M | 107,875 |
| Michael Thomas Henderson Director | May 8, 2026 | Sale(10b5-1 plan) | −2,404 | $72.57 | $174.46K | 166,202 |
| Cameron Turtle Chief Executive Officer, Director | May 1, 2026 | Sale(10b5-1 plan) | −1,700 | $74.23 | $126.19K | 612,840 |
| Cameron Turtle Chief Executive Officer, Director | May 1, 2026 | Sale(10b5-1 plan) | −300 | $74.96 | $22.49K | 612,540 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| King-Jones Heidy Officer | Oct 1, 2026 | 29,335 | $2.61M | Oct 1, 2026 | Exercise of Stock Options |
| Turtle Cameron Director, Officer | Oct 1, 2026 | 45,000 | $4.01M | Oct 1, 2026 | Previously Exercised Stock Options |
| Burrows Scott Officer | Sep 30, 2026 | 17,500 | $1.57M | Sep 30, 2026 | Stock Option Exercise |
| King-Jones Heidy Officer | Sep 1, 2026 | 46,665 | $4.17M | Sep 1, 2026 | Exercise of Stock Options |
| Albers Jeffrey Director | Aug 7, 2026 | 5,000 | $517.10K | Aug 7, 2026 | Exercise of Stock Options |
| Sessions, Llc Director | Aug 7, 2026 | 18,000 | $1.86M | Aug 7, 2026 | Open Market Purchase |
| Burrows Scott Officer | Aug 3, 2026 | 30,000 | $2.95M | Aug 3, 2026 | Exercise of Stock Options |
| Turtle Cameron Director, Officer | Jul 1, 2026 | 45,000 | $4.00M | Jul 1, 2026 | Previously Exercised Stock Options |
| Burrows Scott Officer | Jun 25, 2026 | 15,000 | $1.31M | Jun 25, 2026 | Stock Option Exercise |
| Healthcare Fund II L.P. Fairmount Director | Jun 23, 2026 | 4,684,781 | $399.66M | Jun 23, 2026 | Acquired in reverse merger transaction |
| Henderson Michael Director | Jun 22, 2026 | 20,000 | $1.77M | Jun 22, 2026 | Restricted Stock Units |
| Sloan Sheldon Officer | Jun 3, 2026 | 16,667 | $1.15M | Jun 3, 2026 | Exercise of Stock Options |
| Henderson Michael Director | May 8, 2026 | 80,000 | $5.85M | May 8, 2026 | Restricted Stock Units |
| Burrows Scott Officer | May 1, 2026 | 27,500 | $2.05M | May 1, 2026 | Exercise of Stock Options |
| Sloan Sheldon Officer | May 1, 2026 | 78,333 | $5.83M | May 1, 2026 | Exercise of Stock Options |